698 Stock Overview
A biopharmaceutical company, develops precision T cell therapies to treat solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Achilles Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.86 |
| 52 Week High | US$1.44 |
| 52 Week Low | US$0.65 |
| Beta | 1.37 |
| 1 Month Change | 0% |
| 3 Month Change | -3.35% |
| 1 Year Change | 8.81% |
| 3 Year Change | -82.20% |
| 5 Year Change | n/a |
| Change since IPO | -92.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 698 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | -0.4% |
| 1Y | 8.8% | -10.2% | 7.9% |
Return vs Industry: 698 exceeded the German Biotechs industry which returned -10.5% over the past year.
Return vs Market: 698 matched the German Market which returned 9.2% over the past year.
Price Volatility
| 698 volatility | |
|---|---|
| 698 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 698's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 698's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 210 | Iraj Ali | www.achillestx.com |
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
Achilles Therapeutics plc Fundamentals Summary
| 698 fundamental statistics | |
|---|---|
| Market cap | €37.90m |
| Earnings (TTM) | -€63.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 698 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 698 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$66.88m |
| Earnings | -US$66.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 698 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 05:00 |
| End of Day Share Price | 2024/09/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Achilles Therapeutics plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Ingrid Gafanhão | Bryan Garnier & Co |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |